1-3 of 3
Nishan Rajakumaraswamy, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Idelalisib Treatment Interruption with or without Dose Reduction on Outcomes in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Shuo Ma, MD PhD, Rebecca J Chan, MD PhD, Lin Gu, MS, Guan Xing, PhD, Nishan Rajakumaraswamy, MD, Bianca Ruzicka, PhD, Nina D. Wagner-Johnston, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5468.
https://doi.org/10.1182/blood-2019-124541
Published: 2019
Journal Articles

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Sven de Vos, MD PhD, Gilles A. Salles, MD PhD, Wojciech Jurczak, MD PhD, Nishan Rajakumaraswamy, MD, Guan Xing, PhD, Ajay K. Gopal, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4006.
https://doi.org/10.1182/blood-2019-121936
Published: 2019
Journal Articles

A Multicentre, Retrospective Observational Study to Evaluate the Clinical Outcomes of Patients with Chronic Lymphocytic Leukaemia (CLL) Treated with Idelalisib and Rituximab in the UK (RETRO-idel) - a Cohort of 110 Patients

Toby A. Eyre, Gavin Preston, MD, Huseini Hatimbhai Kagdi, MD PhD MBBS, FRCPath, MRCP, Amin Islam, MD, Toby Nicholson, FRCPath, MBBS, MRCP, BA, Christopher Fegan, MB, MD FRCP, FRCPath, Harry W Smith, BSc, MSc, Adam P Cursley, MSc, Heribert Ramroth, PhD, Nishan Rajakumaraswamy, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1762.
https://doi.org/10.1182/blood-2019-126845
Published: 2019